ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 359

Improved Radiological Outcome of Rheumatoid Arthritis: Early Treatment with methotrexate might be a key Prognostic Factor

Christoph Fiehn1, Elisabeth Belke-Voss1, Dietmar Krause2, Siegfried Wassenberg3 and Rolf Rau4, 1ACURA Centre for Rheumatic Diseases, Baden-Baden, Germany, 2Dept. for Medical Informatics, Biometry and Epidemiology, Ruhr University, Bochum, Germany, 3Rheumaklinik, Evangelisches Fachkrankenhaus Ratingen, Rheumazentrum, Ratingen, Germany, 4Düsseldorf, Germany

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: methotrexate (MTX), Outcome measures, prognostic factors, radiography and rheumatoid arthritis, treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects I: Drug Studies/Drug Safety/Drug Utilization/Disease Activity & Remission

Session Type: Abstract Submissions (ACR)

Background/Purpose: To compare the rate of radiological progression in patients with rheumatoid arthritis (RA) diagnosed in the 1980s with those of the late 1990s until 2005 and to evaluate key factors for differences in prognosis.

Methods: 92 RA patients which were firstly seen in our clinic from 1997 to 2005 and in which baseline and at least one follow up radiograph of hands and feet were available were retrospectively identified. As a control group, 89 RA patients from 1986 to 1990 were matched for the criteria disease duration, age and number of x-ray controls. In both groups patients had a disease duration of less than 5 years at first consultation (mean: 22 ±17 months). Radiologic damage was measured by the Ratingen score (RS).

Results: The baseline RS was significantly lower in the 1997-2005 group compared to the 1986-1990 group (mean 3.8 ±8.7  vs. 7.7 ±13.0 respectively, p<0.0001). This was also the case in the patients firstly seen before the approval of TNF-Inhibitors in 2000 (n=29, mean baseline RS 1997-2000: 2.7 ±4.9; p<0.001 in comparison to 1986-1990). Moreover, the 1997-2005 group showed significantly less radiologic progression than the 1986-1990 group during follow-up (ΔRS/year of 0.95 ±2.19 vs. 5.69 ±8.43; p<0.0001). In the later group more patients (73% vs. 28%; p=0.0001) received methotrexate (MTX), mainly early in the course of the disease. In contrast, the overall rate of DMARD treatment was not significantly different in both groups. Twenty one (23%) of the patients in the later group received biologic drugs, in the majority TNF-Inhibitors. Multivariate analysis showed that early start of MTX (before or directly after first consultation) was a significant predictor of low radiographic progression (p<0.005), as were low ESR at baseline and belonging to the later group. In contrast, neither treatment with glucocorticoids or biologic drugs nor the overall rate of MTX-use were predictive for a better outcome.

Conclusion: Radiologic damage is markedly diminished in RA patients seen since the late 1990s. Early treatment with MTX may be the key factor for this improved prognosis. However, due to the retrospective design of the study, a bias cannot be completely excluded.

Fig: Mean Ratingen scores and radiologic progression in the different groups 1986-90 and 1997-2005 (grey and black). The results of the x-ray analysis were separated in dependence from the time after the first consultation (columns). The differences were statistically significant (p<0.0001) between the two groups at each time point.


Disclosure:

C. Fiehn,
None;

E. Belke-Voss,
None;

D. Krause,
None;

S. Wassenberg,
None;

R. Rau,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/improved-radiological-outcome-of-rheumatoid-arthritis-early-treatment-with-methotrexate-might-be-a-key-prognostic-factor/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology